A method of mixing a pharmaceutical solution including adding a gas into an interior compartment of a mix bag to form a headspace. The interior compartment of the mix bag includes a top portion and a bottom portion. The headspace adjacent to the top portion contains gas. The method includes adding a solvent into the mix bag, and establishing a bubble column in the interior compartment by activating a recirculation assembly. The recirculation assembly includes a connecting pathway operably coupled to a recirculation pump. A first end of the connecting pathway is coupled to a top gas recirculation port and a second end is coupled to a bottom gas recirculation port of the mix bag such that the recirculation pump draws the gas from the headspace and delivers the gas to the interior compartment via the bottom gas recirculation port. The method includes adding a solute into the mix bag.

A method of mixing a pharmaceutical solution including adding a gas into an interior compartment of a mix bag to form a headspace. The interior compartment of the mix bag includes a top portion and a bottom portion. The headspace adjacent to the top portion contains gas. The method includes adding a solvent into the mix bag, and establishing a bubble column in the interior compartment by activating a recirculation assembly. The recirculation assembly includes a connecting pathway operably coupled to a recirculation pump. A first end of the connecting pathway is coupled to a top gas recirculation port and a second end is coupled to a bottom gas recirculation port of the mix bag such that the recirculation pump draws the gas from the headspace and delivers the gas to the interior compartment via the bottom gas recirculation port. The method includes adding a solute into the mix bag.

A drug delivery system includes a packaging housing a first component including at least one of a drug product, a diluent, a saline solution, or an IV stabilizing solution (“IVSS”) and a second component comprising at least one of the drug product, the diluent, the saline solution, and the IVSS, the first component being different than the second component. The first component is disposed in a first container in a storage state and the first container is positioned in a first compartment of the packaging housing. The second component is disposed in a second container in a storage state and the second container is positioned in a second compartment of the packaging housing. At least one of the first compartment and the second compartment may include an individual seal and wherein each of the individual seals and the first and second compartments are sterilized.

A drug delivery system includes a packaging housing a first component including at least one of a drug product, a diluent, a saline solution, or an IV stabilizing solution (“IVSS”) and a second component comprising at least one of the drug product, the diluent, the saline solution, and the IVSS, the first component being different than the second component. The first component is disposed in a first container in a storage state and the first container is positioned in a first compartment of the packaging housing. The second component is disposed in a second container in a storage state and the second container is positioned in a second compartment of the packaging housing. At least one of the first compartment and the second compartment may include an individual seal and wherein each of the individual seals and the first and second compartments are sterilized.

Aspects include systems having an intravenous fluid bag, a tubing line assembly including tubing connected to a connector and a purge valve assembly including a spike and an outer housing. The outer housing is connected to the spike and includes a receiving end portion configured to receive the connector. The purge valve assembly further has a check valve provided within the outer housing. Generally, the purge valve assembly interconnects the fluid bag to the fluid tubing assembly for removal of air from the fluid bag prior to connection to the tubing line assembly. Various methods and purge valve assemblies provide a rapid infusion system for use. The purge valve assemblies do not require the user to reinsert the connector or spike into the intravenous fluid bag, creating a sterile solution to preparing the intravenous fluid for rapid infusion while reducing the risk of air emboli.

Aspects include systems having an intravenous fluid bag, a tubing line assembly including tubing connected to a connector and a purge valve assembly including a spike and an outer housing. The outer housing is connected to the spike and includes a receiving end portion configured to receive the connector. The purge valve assembly further has a check valve provided within the outer housing. Generally, the purge valve assembly interconnects the fluid bag to the fluid tubing assembly for removal of air from the fluid bag prior to connection to the tubing line assembly. Various methods and purge valve assemblies provide a rapid infusion system for use. The purge valve assemblies do not require the user to reinsert the connector or spike into the intravenous fluid bag, creating a sterile solution to preparing the intravenous fluid for rapid infusion while reducing the risk of air emboli.

The present invention relates to compositions and methods for minimizing protein loss (e.g., due to adsorption to solid surfaces) at low protein concentrations. Inventions disclosed herein generally relate to the field of compositions comprising proteins, in particular, pharmaceutical compositions comprising therapeutic proteins at low protein concentrations. Inventions disclosed herein also relate to methods of administering the composition to a subject in need thereof.

The present invention relates to compositions and methods for minimizing protein loss (e.g., due to adsorption to solid surfaces) at low protein concentrations. Inventions disclosed herein generally relate to the field of compositions comprising proteins, in particular, pharmaceutical compositions comprising therapeutic proteins at low protein concentrations. Inventions disclosed herein also relate to methods of administering the composition to a subject in need thereof.

The invention relates to a flexible container/multi-chamber container with selective dissolved gas content for stabilizing at least one compound of a medical product having a selective gas requirement for remaining stable, comprising a solution comprising the at least one compound and a fil material from which the container is made that provides for high gas-barrier for the said gas. The at least one compound may be selenium in the form of Se(IV) and is preferably selected from the group consisting of sodium selenite, selenous acid and selenium dioxide. The selective gas may be oxygen, and the headspace of the oxygen maintains the solution to comprise dissolved oxygen (DO) at a level of 0.5 ppm to 8 ppm.

The invention relates to a flexible container/multi-chamber container with selective dissolved gas content for stabilizing at least one compound of a medical product having a selective gas requirement for remaining stable, comprising a solution comprising the at least one compound and a fil material from which the container is made that provides for high gas-barrier for the said gas. The at least one compound may be selenium in the form of Se(IV) and is preferably selected from the group consisting of sodium selenite, selenous acid and selenium dioxide. The selective gas may be oxygen, and the headspace of the oxygen maintains the solution to comprise dissolved oxygen (DO) at a level of 0.5 ppm to 8 ppm.